1. Home
  2. IDR vs PEPG Comparison

IDR vs PEPG Comparison

Compare IDR & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Idaho Strategic Resources Inc.

IDR

Idaho Strategic Resources Inc.

HOLD

Current Price

$44.97

Market Cap

378.0M

ML Signal

HOLD

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$5.51

Market Cap

317.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDR
PEPG
Founded
1996
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
378.0M
317.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
IDR
PEPG
Price
$44.97
$5.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$17.50
$9.50
AVG Volume (30 Days)
438.7K
737.8K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
52.70
N/A
EPS
0.73
N/A
Revenue
$35,424,313.00
N/A
Revenue This Year
$21.91
N/A
Revenue Next Year
$5.47
N/A
P/E Ratio
$59.16
N/A
Revenue Growth
61.35
N/A
52 Week Low
$9.67
$0.88
52 Week High
$54.70
$6.72

Technical Indicators

Market Signals
Indicator
IDR
PEPG
Relative Strength Index (RSI) 65.76 51.13
Support Level $41.65 $5.08
Resistance Level $46.33 $6.72
Average True Range (ATR) 3.21 0.43
MACD 0.45 -0.08
Stochastic Oscillator 95.59 42.11

Price Performance

Historical Comparison
IDR
PEPG

About IDR Idaho Strategic Resources Inc.

Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Share on Social Networks: